Price T Rowe Associates Inc Alkermes Plc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Alkermes Plc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 12,998,606 shares of ALKS stock, worth $413 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
12,998,606
Previous 11,012,312
18.04%
Holding current value
$413 Million
Previous $265 Million
37.09%
% of portfolio
0.04%
Previous 0.03%
Shares
16 transactions
Others Institutions Holding ALKS
# of Institutions
358Shares Held
180MCall Options Held
175KPut Options Held
96.6K-
Black Rock Inc. New York, NY29.1MShares$924 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$602 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA12.7MShares$402 Million0.06% of portfolio
-
State Street Corp Boston, MA9.19MShares$292 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.65MShares$211 Million2.97% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $5.22B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...